Atypical femoral fractures (AFF) are related to long-term therapy with bisphosphonates in the setting of osteoporosis. This case study reviews the diagnosis and treatment of the condition.
Biologic Therapies for Metabolic Bone Disease
Denosumab and romosozumab work on different pathways but offer new options for patients with low bone mass as primary therapy and for those unresponsive to or contraindicated for bisphosphonates.